Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC).
W. M. Stadler
No relevant relationships to disclose
D. J. Vaughn
Research Funding - Bristol-Myers Squibb
G. Sonpavde
No relevant relationships to disclose
N. J. Vogelzang
Consultant or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Celgene; Cougar Biotechnology; Eisai; Genentech; GlaxoSmithKline; Johnson & Johnson; Pfizer; Takeda
Honoraria - Amgen; Bayer; Cougar Biotechnology; Genentech; Johnson & Johnson; Lilly; Novartis; Pfizer; Sanofi
Research Funding - Cougar Biotechnology; GlaxoSmithKline; Johnson & Johnson; Novartis; Pfizer; Takeda
S. T. Tagawa
No relevant relationships to disclose
D. P. Petrylak
No relevant relationships to disclose
P. J. Rosen
No relevant relationships to disclose
C. Lin
Consultant or Advisory Role - Boehringer Ingelheim
J. F. Mahoney
No relevant relationships to disclose
S. S. Modi
No relevant relationships to disclose
P. Lee
No relevant relationships to disclose
M. S. Ernstoff
Research Funding - Boehringer Ingelheim
W. Su
No relevant relationships to disclose
A. I. Spira
No relevant relationships to disclose
M. Ould Kaci
Employment or Leadership Position - Boehringer Ingelheim
T. Taube
Employment or Leadership Position - Boehringer Ingelheim
Jane Watrous
Employment or Leadership Position - Boehringer Ingelheim
R. Vinisko
No relevant relationships to disclose
C. Schloss
Employment or Leadership Position - Boehringer Ingelheim
C. Zhao
Employment or Leadership Position - Boehringer Ingelheim
M. A. Carducci
Consultant or Advisory Role - Boehringer Ingelheim (U)